About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...

Obesity is associated with increased odds of mood and anxiety disorders, including more serious mental health conditions such as schizophrenia and bipolar disease.

Allurion (ALUR) launched a new program to provide patients access to compounded weight-loss drugs Monday after months of pitching its own weight-loss solution — an ingestible balloon — as an ...

Now, Innovent has said it plans to file for NMPA approval of the drug in diabetes "in the near term." "Mazdutide is the first and fastest-developed [GLP-1/glucagon] dual agonist in the world ...

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

Women, especially those who had high blood pressure during pregnancy or entered menopause before age 45, are among those with ...

The guidelines also suggest new GLP ... one medication does not work, providers and patients should not hesitate to add another." The updated guidelines encourage people to follow the ...

GLP-1 agonists are only available through ... and how to incorporate it into a healthy weight management plan, alongside a balanced diet, healthy lifestyle, and regular physical activity.

Obesity is a chronic, progressive disease that can lead to serious health complications, reduced quality of life, and ...

The new rule would expand access to the drugs for 3.4 million Americans who use Medicare and another 4 million people ...